tiprankstipranks
Buy Rating for Vaxcyte Driven by Anticipated Positive Phase 2 Data and Undervalued Stock Potential
PremiumRatingsBuy Rating for Vaxcyte Driven by Anticipated Positive Phase 2 Data and Undervalued Stock Potential
27d ago
Vaxcyte Advances Vaccine Pipeline with Strong Financial Backing
Premium
Company Announcements
Vaxcyte Advances Vaccine Pipeline with Strong Financial Backing
28d ago
Vaxcyte’s Promising Growth in the PCV Market: Analyst Recommends Buy Rating
Premium
Ratings
Vaxcyte’s Promising Growth in the PCV Market: Analyst Recommends Buy Rating
28d ago
Vaxcyte’s Promising Market Position and Innovative Approach Justify Buy Rating
PremiumRatingsVaxcyte’s Promising Market Position and Innovative Approach Justify Buy Rating
2M ago
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Premium
The Fly
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
2M ago
Vaxcyte initiated with a Buy at Goldman Sachs
Premium
The Fly
Vaxcyte initiated with a Buy at Goldman Sachs
3M ago
Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
PremiumCompany AnnouncementsVaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
5M ago
Vaxcyte Reports Progress and Strengthens Financial Position
Premium
Company Announcements
Vaxcyte Reports Progress and Strengthens Financial Position
5M ago
Vaxcyte reports Q3 EPS (83c), consensus ($1.13)
Premium
The Fly
Vaxcyte reports Q3 EPS (83c), consensus ($1.13)
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100